Articles

Find an Article

Filter articles

Applied Filters

Showing 1 to 10 of 320 results

The doctrine of equivalents in the medtech arena

US18-11-2020Christopher Bright and Nathan Smith

The role of the doctrine of equivalents in assessing the value of, and risks associated with, medtech patents is often overlooked. Christopher Bright and Nathan Smith of Morgan Lewis report.

Five core IP legal principles in life sciences

09-07-2020Jonathan Harris, Ian Lodovice, and Nisan Zaghi

In the high stakes world of life sciences, the strength of a company’s IP portfolio can determine the value of a corporate transaction, argue Jonathan Harris and Nisan Zaghi of Axinn, and Ian Lodovice of Biogen.

Lanham Act: brand owners’ current weapon of choice

11-06-2020

As opportunistic price-gougers look to capitalise on the COVID-19 pandemic, brands such as 3M have turned to trademark law to try and stop them. Brian Michalek and Erin Westbrook of Saul Ewing Arnstein & Lehr report.

Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?

EU20-05-2020Paul Williams

Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.

Why things could get ugly over COVID-19 patents

30-04-2020Mark Engelman

Foreign patents protecting COVID-19 treatments may stall efforts to protect citizens, says Mark Engelman of Hardwicke chambers.

COVID-19: patent procurement and licensing

US31-03-2020Jonathan Tietz, Jason Mock, and Kristel Schorr

Jonathan Tietz, Jason Mock, and Kristel Schorr of Foley & Lardner offer their thoughts on patent procurement and licensing for COVID-19-related technologies.

Event preview: Life Sciences IP Due Diligence summit

US22-10-2019

The Annual Summit on Life Sciences IP Due Diligence to be held on November 14 and 15 in Boston, MA, is a one-of-a-kind, interactive forum where diligence experts discuss best practices and strategies for executing a proper IP due diligence analysis for incumbent portfolios and those of potential targets.

Medicinal cannabis: what next for Brazil?

Brazil21-10-2019Ludmila Kawakami and Ana Paula Couto

Tensions between public use, drug laws and regulators make IP around Cannabis a complex situation, explains Ludmila Kawakami and Ana Paula D. C. Couto of Di Blasi, Parente & Associados.

Conference preview: LSX World Congress USA

04-10-2019Paul Gilbertson

LSX World Congress USA brings life sciences investment and partnering to Boston.

Pharma: A Mexican tradeoff

Mexico30-09-2019Margarita Guerrero Gonzalez

While providing benefits to Mexico’s biologics system, the USMCA may also increase costs for citizens, argues Margarita Guerrero Gonzalez of Uhthoff, Gomez Vega & Uhthoff.

Showing 1 to 10 of 320 results

LSIPR